Currently out of the existing stock ratings of Hartaj Singh, 159 are a BUY (94.08%), 1 are a SELL (0.59%), 9 are a HOLD (5.33%).

Hartaj Singh

Work Performance Price Targets & Ratings Chart

Analyst Hartaj Singh, currently employed at OPPENHEIMER, carries an average stock price target met ratio of 44.61% that have a potential upside of 36.17% achieved within 233 days.

Hartaj Singh’s has documented 338 price targets and ratings displayed on 29 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on SRPT, Sarepta Therapeutics at 29-Jul-2025.

Wall Street Analyst Hartaj Singh

Analyst best performing recommendations are on ONCT (ONCTERNAL THERAPEUTICS).
The best stock recommendation documented was for MRNA (MODERNA) at 4/15/2020. The price target of $43 was fulfilled within 2 days with a profit of $5.75 (15.44%) receiving and performance score of 77.18.

Average potential price target upside

of $148.82 (25.35%) on REGN (REGENERON PHARMACEUTICALS).
of $69.22 (60.29%) on INO (INOVIO PHARMACEUTICALS).
of $61.2 (38.97%) on UTHR (UNITED THERAPEUTICS).

ALXN Alexion Pharmaceuticals CATB Catabasis Pharmaceuticals GILD Gilead Sciences INO Inovio Pharmaceuticals LIFE aTyr Pharma MRNA Moderna REGN Regeneron Pharmaceuticals SBBP Strongbridge Biopharma plc SNSS Sunesis Pharmaceuticals UTHR United Therapeutics VIRX Viracta Therapeutics VRTX Vertex Pharmaceuticals SRPT Sarepta Therapeutics ELOX Eloxx Pharmaceuticals BMEA Biomea Fusion FSTX FStar Therapeutics ONCT Oncternal Therapeutics SPRB Spruce Biosciences GANX Gain Therapeutics ATXS Astria Therapeutics CLLS Cellectis SA ICVX Icosavax NBSE NeuBase Therapeutics OPT Opthea Ltd ORTX Orchard Therapeutics PLC TRDA Entrada Therapeutics ARQL ArQule CELG Celgene SNDX Syndax Pharmaceuticals

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Hartaj Singh (OPPENHEIMER)